Navigation Links
Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions
Date:6/24/2011

6 kg/m2 and mean A1C 8.0 percent.

Key Findings:

  • Lixisenatide once daily achieved its primary endpoint of  non-inferiority in A1C reduction versus exenatide twice daily (LS mean +/- SE change from baseline: -0.79 +/- 0.05 vs. -0.96 +/- 0.05)
  • Improvements in mean fasting plasma glucose – measurement of blood glucose levels when a patient is fasting – (LS mean +/- SE change from baseline: -22.0 +/- 2.1 vs. -26.1 +/- 2.1) and the percentage of patients achieving the study target A1C < 7.0 percent (48.5% vs. 49.8%) were comparable between groups
  • Mean body weight significantly decreased from baseline in the lixisenatide group compared to the exenatide group (94.5 to 91.7 kg with lixisenatide vs. 96.7 to 92.9 kg with exenatide)
  • The proportion of patients with serious adverse events was generally comparable between groups
  • Discontinuations due to adverse events (mainly gastrointestinal events including nausea, diarrhea and vomiting) were 33 (10.4%) in the lixisenatide group and 41 (13.0%) in the exenatide group
  • Significantly fewer patients experienced symptomatic hypoglycemia with lixisenatide (2.5% vs. 7.9%, p<0.05), with 6-fold fewer hypoglycemic events (8 vs. 48) versus exenatide
  • More lixisenatide patients tolerated the target dose of 20 microgram per day and completed the trial versus the exenatide 10 mcg target dose (93% vs. 83%)

  • "Lixisenatide  Significantly  Improves  Glycemic  Control  in  Asian  Patients   with  Type  2 Diabetes Insufficiently Controlled on Basal Insulin +/- Sulfonylurea" [ABSTRACT 0278-OR]Data from the GetGoal-L Asia trial, showed in  Asian patients with type 2 diabetes insufficiently controlled by basal insulin +/- sulfonylurea, that lixisenatide once daily significantly improved glycemic control (as  measured by the number of patients reaching  a target A1C < 6.5 percent or
    '/>"/>

    SOURCE Euro RSCG Life
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
    10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
    11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
    (Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
    (Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
    Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
    ... Study Ingredient,s, Impact on North Americans, NEW ... of,Japan today announced that it has selected world-renowned Cardiologist ... KGK Synergize Inc.,to launch a new clinical trial to ... lipid management and the reduction of cardiovascular,risk factors in ...
    ... a 52-week phase 3,study (LEADTM 3) of Novo ... GLP-1 analog, were published online today in The ... produces statistically,significant and sustained improvements in blood sugar ... compared with glimepiride, a widely used,oral anti-diabetic drug. ...
    Cached Medicine Technology:Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels 2Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels 3Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 2Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 3
    (Date:7/11/2014)... Steven Reinberg HealthDay Reporter ... depression may increase the risk for stroke, a new study ... the risk of a stroke or a transient ischemic ... apparently raised stroke or TIA risk by 59 percent. And ... a mini-stroke caused by a temporary blockage of blood flow ...
    (Date:7/11/2014)... the distinguished wedding dress manufacturer and retailer, has recently ... . To top it all off, all these high ... to 65% off. Clients who place orders on the ... Fadhits.com is devoted to designing and selling beautiful wedding ... All its items come with very fast delivery. More ...
    (Date:7/11/2014)... San Francisco shows that an "expressive therapy" group ... living with HIV disclose their health status and ... and quality of their relationships., "Medication alone is ... L. Machtinger, MD, director of the Women,s HIV ... patients are on effective antiretroviral therapy but far ...
    (Date:7/11/2014)... 11, 2014 Bedros Keuilian is known in ... he’s earned by founding the fast-selling fitness franchise in the ... businesses. He works with successful boot camp owners on a ... the traits of the most successful boot camp owners , ... qualities. , “I’ve worked with and coached some of the ...
    (Date:7/11/2014)... When the mercury rises, heat can strain the limits of ... on a heavier load in hot weather to keep body ... Harvard Men's Health Watch . , For otherwise fit, ... their limits and drinking enough fluids. But what about men ... to the heat," says Dr. Joanne Foody, Director of cardiovascular ...
    Breaking Medicine News(10 mins):Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3Health News:Elegant Lace Holiday Dresses Released by Fadhits.com 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 2Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 3
    ... is a form of arthritis where one or more ... in these type of joint problems is the loss ... that moisturizes the area. This fluid is called synovial ... since 1987, after the therapy was proved beneficial in// ...
    ... Institute, has succeeded in finding a new biosensor ... a breakthrough technology that will help scientific researchers ... of neurons, nerve tissue and organic neural networks. ... metal oxide semiconductor technology extended with additional process ...
    ... currently testing the safety of hypothermia as a ... treatment has been shown to be effective for ... effectiveness in treating children with traumatic brain injuries ... excitotoxicity (excessive neurotransmitters released with injury that damage ...
    ... of Durham in England has reported a discovery, that adds ... ones, for breast feeding of babies. Babies who are breast-fed ... than babies who are bottle-fed in bed. The study included ... while they slept. Researchers found that mothers who breast-fed their ...
    ... received a patient, a two-month-old baby with white blood! The ... caused due to a deficiency of lipoprotein lipase. This disease ... said that the baby was brought to the hospital with ... boy child, was found to have lipemic blood. Doctors said ...
    ... study published in the journal, Molecular Psychiatry suggested that scientists ... to sleepwalking. Sleepwalking is a complex disorder and affects around ... of adults. Though the condition is harmless, it may sometimes ... others. Scientists examined a family of genes known as HLA ...
    Cached Medicine News:
    ... is an effective angina relief ... poor targets. Because it is ... the CO2 Heart Laser 2 ... timely operative decisions to revascularize ...
    Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
    TG (Ab) RIA Thyroid Function 014-HD 27.1 Thyroglobulin...
    ... The anti-TG test kit is a solid ... format. It is designed for the quantitative ... (TG) in serum or plasma. The microplate ... Calibrators, controls and patient samples are pipetted ...
    Medicine Products: